Abstract: What`s New for 2022? - Global competitiveness and key competitor percentage market shares. - Market presence across multiple geographies - Strong/Active/Niche/Trivial.

New York, May 10, 2022 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Global Pen Needles Industry" - https://www.reportlinker.com/p06032471/?utm_source=GNW - Online interactive peer-to-peer collaborative bespoke updates - Access to our digital archives and MarketGlass Research Platform - Complimentary updates for one year - Global Pen Needles Market to Reach US$3.3 Billion by the Year 2026 - Injection pen and pen needles have evolved as an alternative to the conventional methods such as the vial method or syringe method for delivering drugs into an individual`s body. Widely used by patients and healthcare providers to administer drugs for various diseases, pen needles have gained traction owing to the favorable reimbursement structure of several countries and advances in therapy. The pen needle market across the world is anticipated to register healthy growth in the years to come, owing to a rise in the number of individuals suffering from various diseases, specially diabetes and others. Preference to minimally invasive processes, expansion in the population of geriatric individuals, and growing awareness among diabetes patients about hassle-free drug delivery are expected to offer newer business opportunities in the market. The launch of various novel products such as short-length and ultra-thin needles that offer enhanced drug delivery systems, and favorable policies drafted by the government are likely to steer market growth in the coming few years. Chronic ailments such as diabetes, multiple sclerosis, osteoporosis, and cardiovascular diseases have been on the rise over the last few years. Treating these kinds of chronic ailments demands weekly or even daily administration of drugs mainly through pen injectors. Pen injectors are witnessing an upsurge in the demand owing to their reliability, ability for being self-administered sans the need for any physician, and easy-to-use attributes. - Amid the COVID-19 crisis, the global market for Pen Needles estimated at US$2.4 Billion in the year 2022, is projected to reach a revised size of US$3.3 Billion by 2026, growing at a CAGR of 8.7% over the analysis period. Standard, one of the segments analyzed in the report, is projected to grow at a 6.9% CAGR to reach US$2.1 Billion by the end of the analysis period. After a thorough analysis of the business implications of the pandemic and its induced economic crisis, growth in the Safety segment is readjusted to a revised 11.4% CAGR for the next 7-year period. This segment currently accounts for a 35.8% share of the global Pen Needles market. The standard pen needles segment is dominant due to its extensive usage by diabetic individuals. Global market for safety needles is influenced by the strong emphasis on user safety and growing demand for cost effective solutions. The market is essentially driven by snowballing healthcare industry concerns over needle stick injuries and worker safety. The U.S. Market is Estimated at $769 Million in 2022, While China is Forecast to Reach $255.8 Million by 2026 - The Pen Needles market in the U.S. is estimated at US$769 Million in the year 2022. The country currently accounts for a 32.52% share in the global market. China, the world`s second largest economy, is forecast to reach an estimated market size of US$255.8 Million in the year 2026 trailing a CAGR of 9.7% through the analysis period. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 7.4% and 7.7% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 7.9% CAGR while Rest of European market (as defined in the study) will reach US$270.6 Million by the end of the analysis period. While developed regions especially the US and Europe remain the dominant forces in the global pen needles market, developing market such as Asia-Pacific emerge as key growth drivers given the rapidly evolving healthcare sector in various countries across the region. Europe is projected to account for a larger share in the worldwide pen needles market, owing to an increase in R&D activities on diabetes care, advancements in technology, and rise in the diabetic population. The market for pen needles in Asia-Pacific region on the other hand is expected to grow rapidly. Growing awareness about the prevalence of medical care as well as treatment, increase in R&D activities, and expanding health care segment are some of the factors fostering growth in the region. Select Competitors (Total 63 Featured) AdvaCare Pharma Allison Medical Inc. ARKRAY, Inc. B. Braun Melsungen AG Becton, Dickinson and Company Berpu Medical Technology Co., Ltd. GlucoRx Limited Hindustan Syringes & Medical Devices Ltd. HTL-STREFA S.A. Iyon Saglik Medical Links Medical Products, Inc. MHC Medical Products, LLC Montméd Inc. Nipro Corporation Novo Nordisk Owen Mumford Ltd. Promisemed Medical Devices Inc. Simple Diagnostics Terumo Europe NV Trividia Health, Inc. UltiMed, Inc. Van Heek Medical Vogt Medical Vertrieb GmbH Ypsomed AG Read the full report: https://www.reportlinker.com/p06032471/?utm_source=GNW I. METHODOLOGY II. EXECUTIVE SUMMARY 1. MARKET OVERVIEW Impact of COVID-19 and a Looming Global Recession The Never-Ending ?Race? Between the Virus & Vaccines Continues. Amidst this Chaotic Battle, Where is the World Economy Heading Now & Beyond? Omicron Variant Brings Back Memories & Fears of the Worst Part of the 2020 Pandemic EXHIBIT 1: Time is of Essence! What We Know So Far - ?Vaccine Efficiency Against New Strains? With New Strains Emerging at an Alarming Rate, Focus Shifts to Booster Doses & Vaccine Tweaking. But How Practical Is It to Implement Them? EXHIBIT 2: With Vaccinated Population Showing Signs of Declining Clinical Protection, Booster Doses Are Emerging Into a Necessity to Restore Vaccine Effectiveness: Number of Booster Doses Administered Per 100 People by Country as of December 2021 How Healthcare Has Been Impacted & Beyond COVID-19 What?s In Store for Healthcare? EXHIBIT 3: Missed Cancer Diagnosis in U.S. as of June 2020 EXHIBIT 4: % Reduction in OR Volumes in the US: Mar 2020-July 2020 EXHIBIT 5: Cumulative Surgery Cancellations Worldwide (In Million) EXHIBIT 6: With the COVID-19 Pandemic Exposing Global Healthcare Unpreparedness, There is Increasing Policy Led Focus on Rebooting Health Systems Worldwide: Current & Required Healthcare Spending as % of GDP COVID-19 and Elective Surgeries COVID-19 Impact on Pen Needles Market Competition EXHIBIT 7: Pen Needles - Global Key Competitors Percentage Market Share in 2022 (E) Competitive Market Presence - Strong/Active/Niche/Trivial for Market Players Worldwide in 2022 (E) Needles: A Prelude Types of Needles An Insight into Pen Needles Pen Needles for Insulin Injection Global Market Analysis and Prospects Global Pen Needles Market Set for a Rapid Growth Standard Pen Needles Dominate, Safety Pen Needles to Witness Fastest Growth Emerging Markets: Focal Point for Future Growth Competitive Landscape Top Pen Needle Products Recent Market Activity WORLD BRANDS 2. FOCUS ON SELECT PLAYERS 3. MARKET TRENDS & DRIVERS Rise in Diabetic Population Continues to Drives Demand for Pen Needles EXHIBIT 8: World Diabetes and Population Statistics (2019, 2030 & 2045) EXHIBIT 9: Global Prevalence of Diabetes: Number of Adults Diagnosed with Diabetes (in Million) by Gender for 2019, 2030 and 2045 EXHIBIT 10: World Diabetes Prevalence (2000-2019) EXHIBIT 11: Top 10 Countries with Highest Number of Adults Diagnosed with Diabetes (in Million) for 2019 and 2045 EXHIBIT 12: Global Diabetes Mellitus Population Breakdown by Geographic Region: 2019, 2030 and 2045? Diabetes Emerges as One of the Leading Causes of Mortality EXHIBIT 13: Diabetes-Related Deaths as % of Total Deaths in Below 60 Years Population by Region: 2019 Growing Prevalence of Chronic Diseases Drive the Demand for Pen Needles EXHIBIT 14: Global Cancer Incidence: Number of New Cancer Cases in Million for the Years 2018, 2020, 2025, 2030, 2035 and 2040 EXHIBIT 15: Global Number of New Cancer Cases and Cancer- related Deaths by Cancer Site for 2018 EXHIBIT 16: Fatalities by Heart Conditions: Estimated Percentage Breakdown for Cardiovascular Disease, Ischemic Heart Disease, Stroke, and Others High Risk of Diabetes in the Fast Expanding Aging Population Benefit Market Expansion EXHIBIT 17: Global Aging Population Statistics for the 65+ Age Group in Million by Geographic Region for the Years 2019, 2025, 2035 and 2050 EXHIBIT 18: Elderly Population (65+ Years) as a % of Total Population by Developed, Less Developed and Least Developed Regions: 2019 & 2030 Pen Needles Gain Traction as Insulin Pens Rise in Popularity for Administering Insulin Smart Insulin Pens: A Growing Area of Interest Increasing Role of Self-Injection Devices in Diabetes Management Needle-Free Alternatives: A Growing Threat Innovative Technologies Revolutionize Pen Needles Market Advancements in Insulin Delivery Methods Drive the Demand for Pen Needles Advancements in Pen Needle Technology Droplet Micron Insulin Needle Represents Innovation in the Diabetes Supply Market MACRO GROWTH DRIVERS Increasing Healthcare Expenditure Aids Pen Drives Market Growth EXHIBIT 19: World Healthcare Expenditure (In US$ Trillion) for the Years for 2017, 2019, 2021, and 2023 Increasing Obesity Levels Underpins Market Growth EXHIBIT 20: Average Per Capita Annual Health Expenditure (In US$) due to Obesity EXHIBIT 21: Obesity Prevalence Rate (%) in Select Countries for the Years 2019 and 2030P Rising Demand for Biosimilar Drugs Propel the Market for Pen Needles 4. GLOBAL MARKET PERSPECTIVE Table 1: World Recent Past, Current & Future Analysis for Pen Needles by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR Table 2: World Historic Review for Pen Needles by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR Table 3: World 15-Year Perspective for Pen Needles by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2012, 2021 & 2027 Table 4: World Recent Past, Current & Future Analysis for Standard by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR Table 5: World Historic Review for Standard by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR Table 6: World 15-Year Perspective for Standard by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2021 & 2027 Table 7: World Recent Past, Current & Future Analysis for Safety by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR Table 8: World Historic Review for Safety by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR Table 9: World 15-Year Perspective for Safety by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2021 & 2027 Table 10: World Recent Past, Current & Future Analysis for Insulin by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR Table 11: World Historic Review for Insulin by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR Table 12: World 15-Year Perspective for Insulin by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2021 & 2027 Table 13: World Recent Past, Current & Future Analysis for Glucagon-Like Peptide-1 (GLP-1) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR Table 14: World Historic Review for Glucagon-Like Peptide-1 (GLP-1) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR Table 15: World 15-Year Perspective for Glucagon-Like Peptide-1 (GLP-1) by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2021 & 2027 Table 16: World Recent Past, Current & Future Analysis for Other Therapies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR Table 17: World Historic Review for Other Therapies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR Table 18: World 15-Year Perspective for Other Therapies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2021 & 2027 III. MARKET ANALYSIS UNITED STATES Table 19: USA Recent Past, Current & Future Analysis for Pen Needles by Type - Standard and Safety - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR Table 20: USA Historic Review for Pen Needles by Type - Standard and Safety Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR Table 21: USA 15-Year Perspective for Pen Needles by Type - Percentage Breakdown of Value Sales for Standard and Safety for the Years 2012, 2021 & 2027 Table 22: USA Recent Past, Current & Future Analysis for Pen Needles by Therapy - Insulin, Glucagon-Like Peptide-1 (GLP-1) and Other Therapies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR Table 23: USA Historic Review for Pen Needles by Therapy - Insulin, Glucagon-Like Peptide-1 (GLP-1) and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR Table 24: USA 15-Year Perspective for Pen Needles by Therapy - Percentage Breakdown of Value Sales for Insulin, Glucagon-Like Peptide-1 (GLP-1) and Other Therapies for the Years 2012, 2021 & 2027 CANADA Table 25: Canada Recent Past, Current & Future Analysis for Pen Needles by Type - Standard and Safety - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR Table 26: Canada Historic Review for Pen Needles by Type - Standard and Safety Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR Table 27: Canada 15-Year Perspective for Pen Needles by Type - Percentage Breakdown of Value Sales for Standard and Safety for the Years 2012, 2021 & 2027 Table 28: Canada Recent Past, Current & Future Analysis for Pen Needles by Therapy - Insulin, Glucagon-Like Peptide-1 (GLP-1) and Other Therapies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR Table 29: Canada Historic Review for Pen Needles by Therapy - Insulin, Glucagon-Like Peptide-1 (GLP-1) and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR Table 30: Canada 15-Year Perspective for Pen Needles by Therapy - Percentage Breakdown of Value Sales for Insulin, Glucagon-Like Peptide-1 (GLP-1) and Other Therapies for the Years 2012, 2021 & 2027 JAPAN Table 31: Japan Recent Past, Current & Future Analysis for Pen Needles by Type - Standard and Safety - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR Table 32: Japan Historic Review for Pen Needles by Type - Standard and Safety Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR Table 33: Japan 15-Year Perspective for Pen Needles by Type - Percentage Breakdown of Value Sales for Standard and Safety for the Years 2012, 2021 & 2027 Table 34: Japan Recent Past, Current & Future Analysis for Pen Needles by Therapy - Insulin, Glucagon-Like Peptide-1 (GLP-1) and Other Therapies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR Table 35: Japan Historic Review for Pen Needles by Therapy - Insulin, Glucagon-Like Peptide-1 (GLP-1) and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR Table 36: Japan 15-Year Perspective for Pen Needles by Therapy - Percentage Breakdown of Value Sales for Insulin, Glucagon-Like Peptide-1 (GLP-1) and Other Therapies for the Years 2012, 2021 & 2027 CHINA Table 37: China Recent Past, Current & Future Analysis for Pen Needles by Type - Standard and Safety - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR Table 38: China Historic Review for Pen Needles by Type - Standard and Safety Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR Table 39: China 15-Year Perspective for Pen Needles by Type - Percentage Breakdown of Value Sales for Standard and Safety for the Years 2012, 2021 & 2027 Table 40: China Recent Past, Current & Future Analysis for Pen Needles by Therapy - Insulin, Glucagon-Like Peptide-1 (GLP-1) and Other Therapies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR Table 41: China Historic Review for Pen Needles by Therapy - Insulin, Glucagon-Like Peptide-1 (GLP-1) and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR Table 42: China 15-Year Perspective for Pen Needles by Therapy - Percentage Breakdown of Value Sales for Insulin, Glucagon-Like Peptide-1 (GLP-1) and Other Therapies for the Years 2012, 2021 & 2027 EUROPE Table 43: Europe Recent Past, Current & Future Analysis for Pen Needles by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR Table 44: Europe Historic Review for Pen Needles by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR Table 45: Europe 15-Year Perspective for Pen Needles by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2012, 2021 & 2027 Table 46: Europe Recent Past, Current & Future Analysis for Pen Needles by Type - Standard and Safety - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR Table 47: Europe Historic Review for Pen Needles by Type - Standard and Safety Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR Table 48: Europe 15-Year Perspective for Pen Needles by Type - Percentage Breakdown of Value Sales for Standard and Safety for the Years 2012, 2021 & 2027 Table 49: Europe Recent Past, Current & Future Analysis for Pen Needles by Therapy - Insulin, Glucagon-Like Peptide-1 (GLP-1) and Other Therapies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR Table 50: Europe Historic Review for Pen Needles by Therapy - Insulin, Glucagon-Like Peptide-1 (GLP-1) and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR Table 51: Europe 15-Year Perspective for Pen Needles by Therapy - Percentage Breakdown of Value Sales for Insulin, Glucagon-Like Peptide-1 (GLP-1) and Other Therapies for the Years 2012, 2021 & 2027 FRANCE Table 52: France Recent Past, Current & Future Analysis for Pen Needles by Type - Standard and Safety - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR Table 53: France Historic Review for Pen Needles by Type - Standard and Safety Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR Table 54: France 15-Year Perspective for Pen Needles by Type - Percentage Breakdown of Value Sales for Standard and Safety for the Years 2012, 2021 & 2027 Table 55: France Recent Past, Current & Future Analysis for Pen Needles by Therapy - Insulin, Glucagon-Like Peptide-1 (GLP-1) and Other Therapies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR Table 56: France Historic Review for Pen Needles by Therapy - Insulin, Glucagon-Like Peptide-1 (GLP-1) and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR Table 57: France 15-Year Perspective for Pen Needles by Therapy - Percentage Breakdown of Value Sales for Insulin, Glucagon-Like Peptide-1 (GLP-1) and Other Therapies for the Years 2012, 2021 & 2027 GERMANY Table 58: Germany Recent Past, Current & Future Analysis for Pen Needles by Type - Standard and Safety - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR Table 59: Germany Historic Review for Pen Needles by Type - Standard and Safety Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR Table 60: Germany 15-Year Perspective for Pen Needles by Type - Percentage Breakdown of Value Sales for Standard and Safety for the Years 2012, 2021 & 2027 Table 61: Germany Recent Past, Current & Future Analysis for Pen Needles by Therapy - Insulin, Glucagon-Like Peptide-1 (GLP-1) and Other Therapies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR Table 62: Germany Historic Review for Pen Needles by Therapy - Insulin, Glucagon-Like Peptide-1 (GLP-1) and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR Table 63: Germany 15-Year Perspective for Pen Needles by Therapy - Percentage Breakdown of Value Sales for Insulin, Glucagon-Like Peptide-1 (GLP-1) and Other Therapies for the Years 2012, 2021 & 2027 ITALY Table 64: Italy Recent Past, Current & Future Analysis for Pen Needles by Type - Standard and Safety - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR Table 65: Italy Historic Review for Pen Needles by Type - Standard and Safety Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR Table 66: Italy 15-Year Perspective for Pen Needles by Type - Percentage Breakdown of Value Sales for Standard and Safety for the Years 2012, 2021 & 2027 Table 67: Italy Recent Past, Current & Future Analysis for Pen Needles by Therapy - Insulin, Glucagon-Like Peptide-1 (GLP-1) and Other Therapies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR Table 68: Italy Historic Review for Pen Needles by Therapy - Insulin, Glucagon-Like Peptide-1 (GLP-1) and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR Table 69: Italy 15-Year Perspective for Pen Needles by Therapy - Percentage Breakdown of Value Sales for Insulin, Glucagon-Like Peptide-1 (GLP-1) and Other Therapies for the Years 2012, 2021 & 2027 UNITED KINGDOM Table 70: UK Recent Past, Current & Future Analysis for Pen Needles by Type - Standard and Safety - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR Table 71: UK Historic Review for Pen Needles by Type - Standard and Safety Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR Table 72: UK 15-Year Perspective for Pen Needles by Type - Percentage Breakdown of Value Sales for Standard and Safety for the Years 2012, 2021 & 2027 Table 73: UK Recent Past, Current & Future Analysis for Pen Needles by Therapy - Insulin, Glucagon-Like Peptide-1 (GLP-1) and Other Therapies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR Table 74: UK Historic Review for Pen Needles by Therapy - Insulin, Glucagon-Like Peptide-1 (GLP-1) and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR Table 75: UK 15-Year Perspective for Pen Needles by Therapy - Percentage Breakdown of Value Sales for Insulin, Glucagon-Like Peptide-1 (GLP-1) and Other Therapies for the Years 2012, 2021 & 2027 SPAIN Table 76: Spain Recent Past, Current & Future Analysis for Pen Needles by Type - Standard and Safety - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR Table 77: Spain Historic Review for Pen Needles by Type - Standard and Safety Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR Table 78: Spain 15-Year Perspective for Pen Needles by Type - Percentage Breakdown of Value Sales for Standard and Safety for the Years 2012, 2021 & 2027 Table 79: Spain Recent Past, Current & Future Analysis for Pen Needles by Therapy - Insulin, Glucagon-Like Peptide-1 (GLP-1) and Other Therapies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR Table 80: Spain Historic Review for Pen Needles by Therapy - Insulin, Glucagon-Like Peptide-1 (GLP-1) and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR Table 81: Spain 15-Year Perspective for Pen Needles by Therapy - Percentage Breakdown of Value Sales for Insulin, Glucagon-Like Peptide-1 (GLP-1) and Other Therapies for the Years 2012, 2021 & 2027 RUSSIA Table 82: Russia Recent Past, Current & Future Analysis for Pen Needles by Type - Standard and Safety - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR Table 83: Russia Historic Review for Pen Needles by Type - Standard and Safety Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR Table 84: Russia 15-Year Perspective for Pen Needles by Type - Percentage Breakdown of Value Sales for Standard and Safety for the Years 2012, 2021 & 2027 Table 85: Russia Recent Past, Current & Future Analysis for Pen Needles by Therapy - Insulin, Glucagon-Like Peptide-1 (GLP-1) and Other Therapies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR Table 86: Russia Historic Review for Pen Needles by Therapy - Insulin, Glucagon-Like Peptide-1 (GLP-1) and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR Table 87: Russia 15-Year Perspective for Pen Needles by Therapy - Percentage Breakdown of Value Sales for Insulin, Glucagon-Like Peptide-1 (GLP-1) and Other Therapies for the Years 2012, 2021 & 2027 REST OF EUROPE Table 88: Rest of Europe Recent Past, Current & Future Analysis for Pen Needles by Type - Standard and Safety - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR Table 89: Rest of Europe Historic Review for Pen Needles by Type - Standard and Safety Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR Table 90: Rest of Europe 15-Year Perspective for Pen Needles by Type - Percentage Breakdown of Value Sales for Standard and Safety for the Years 2012, 2021 & 2027 Table 91: Rest of Europe Recent Past, Current & Future Analysis for Pen Needles by Therapy - Insulin, Glucagon-Like Peptide-1 (GLP-1) and Other Therapies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR Table 92: Rest of Europe Historic Review for Pen Needles by Therapy - Insulin, Glucagon-Like Peptide-1 (GLP-1) and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR Table 93: Rest of Europe 15-Year Perspective for Pen Needles by Therapy - Percentage Breakdown of Value Sales for Insulin, Glucagon-Like Peptide-1 (GLP-1) and Other Therapies for the Years 2012, 2021 & 2027 ASIA-PACIFIC Table 94: Asia-Pacific Recent Past, Current & Future Analysis for Pen Needles by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR Table 95: Asia-Pacific Historic Review for Pen Needles by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR Table 96: Asia-Pacific 15-Year Perspective for Pen Needles by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2012, 2021 & 2027 Table 97: Asia-Pacific Recent Past, Current & Future Analysis for Pen Needles by Type - Standard and Safety - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR Table 98: Asia-Pacific Historic Review for Pen Needles by Type - Standard and Safety Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR Table 99: Asia-Pacific 15-Year Perspective for Pen Needles by Type - Percentage Breakdown of Value Sales for Standard and Safety for the Years 2012, 2021 & 2027 Table 100: Asia-Pacific Recent Past, Current & Future Analysis for Pen Needles by Therapy - Insulin, Glucagon-Like Peptide-1 (GLP-1) and Other Therapies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR Table 101: Asia-Pacific Historic Review for Pen Needles by Therapy - Insulin, Glucagon-Like Peptide-1 (GLP-1) and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR Table 102: Asia-Pacific 15-Year Perspective for Pen Needles by Therapy - Percentage Breakdown of Value Sales for Insulin, Glucagon-Like Peptide-1 (GLP-1) and Other Therapies for the Years 2012, 2021 & 2027 AUSTRALIA Table 103: Australia Recent Past, Current & Future Analysis for Pen Needles by Type - Standard and Safety - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR Table 104: Australia Historic Review for Pen Needles by Type - Standard and Safety Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR Table 105: Australia 15-Year Perspective for Pen Needles by Type - Percentage Breakdown of Value Sales for Standard and Safety for the Years 2012, 2021 & 2027 Table 106: Australia Recent Past, Current & Future Analysis for Pen Needles by Therapy - Insulin, Glucagon-Like Peptide-1 (GLP-1) and Other Therapies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR Table 107: Australia Historic Review for Pen Needles by Therapy - Please contact our Customer Support Center to get the complete Table of Contents Read the full report: https://www.reportlinker.com/p06032471/?utm_source=GNW About Reportlinker ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place. __________________________

The bank holding company's stock ended its first day of trading at less than the offering price because of an aberrant trade.

Rivian said it was on track to open its new $5 billion Georgia factory in 2024, and that it will produce its new R2 vehicle there in 2025. On the post-earnings conference call, Rivian CFO Claire McDonough confirmed the R2 would be a mid-size SUV.

Shares of Squarespace Inc. were up about 14% in premarket trading Thursday after the company, which enables people to build websites, topped expectations with its latest quarterly revenue and upped its outlook for the full year. The company posted a first-quarter net loss of $92.9 million, or 67 cents a share, compared with a loss of $2.1 million, or 11 cents a share, in the year-earlier quarter. Squarespace's revenue climbed to $207.8 million from $179.6 million, while analysts tracked by FactS

(Bloomberg) -- The Swiss franc weakened to briefly reach parity with the greenback for the first time since late 2019, as the dollar’s role as the preferred haven trade grows amid turmoil in global markets.Most Read from BloombergSony PlayStation Staff Fume Over CEO’s Abortion CommentsCrypto Billionaires’ Vast Fortunes Are Destroyed in WeeksMore Than $200 Billion Wiped Off Cryptocurrency Market in a DayNike Escalates StockX Feud, Says Site Is Selling Fake ShoesStocks End Almost Flat After Suffer

Raymond James has reiterated Outperform rating on LumiraDx Limited's (NASDAQ: LMDX) shares after 1Q revenue beat but lower than expected margins that ultimately do very little to impact long-term views of the company. They lowered the price target from $9 to $7. Revenues were 7% above Raymond James' view and 12% above consensus. The beat was driven by Fast Lab instead of platform revenues, which were below analyst view but mainly on a lack of instrument revenues as most went into the field free

Raising interest rates might kill the housing market and choke off price increases temporarily, but it won't solve the problem of an inadequate supply of homes.

A continued drop through the 50-day line and the 10-week moving average spurs another defensive sell rule.

Porsche Automobil Holding SE cautioned on Friday that the feasibility of a listing of luxury sportscar maker Porsche AG, planned for the fourth quarter of this year, depended on numerous factors including market conditions. "We are working on financing plans in order to be robust in different valuation scenarios for an IPO (initial public offering)," Porsche SE chairman Hans-Dieter Poetsch said. "The actual feasibility of the IPO depends on a large number of different influencing factors... final decisions have not yet been made."

The rout continues in tech. One long-time tech CEO shares his perspective.

A faster slowdown in the central bank’s favored inflation metric alongside a brewing storm in the high-yield credit market might allow Fed policy makers to prioritize growth over the inflation fight.

The company hired a financial adviser last October to explore the sale of its process technology division.

(Bloomberg) -- Amazon.com Inc. shareholders should vote to reject the pay packages of Chief Executive Officer Andy Jassy and other top leaders, two influential investor advisory firms recommended, citing massive stock grants executives are set to receive regardless of how well the company performs in the coming years. Most Read from BloombergElon Musk Sows Doubt Over His $44 Billion Twitter TakeoverSony PlayStation Staff Fume Over CEO’s Abortion CommentsApple Testing iPhones That Ditch Lightning

Do you have the right portfolio for your retirement savings? When it comes to long-term investing, the biggest issue — by far — is overall asset allocation: How much to stocks, sectors, assets and so on. Picking individual securities within those asset classes — individual stocks or bonds, for example — usually turns out to be much less important.

U.S. stocks ended a whipsaw session slightly lower on Thursday, as investors juggled signs of peaking inflation with fears that it could remain elevated, prompting ever more aggressive tightening from the Federal Reserve. All three major U.S. stock indexes seesawed and the S&P 500 came within striking distance of confirming it entered a bear market after swooning from its all-time high reached on Jan. 3.

With competition at a fever pitch for skilled manufacturing talent, employers are more focused than ever on diversity, equity and inclusion.

(Bloomberg) -- Mexico’s central bank boosted borrowing costs by half a percentage point in a widely-anticipated move to tame inflation that’s at two-decade highs, adding that it could consider increasing the pace of hikes going forward.Most Read from BloombergSony PlayStation Staff Fume Over CEO’s Abortion CommentsCrypto Billionaires’ Vast Fortunes Are Destroyed in WeeksMore Than $200 Billion Wiped Off Cryptocurrency Market in a DayNike Escalates StockX Feud, Says Site Is Selling Fake ShoesStock

Biotech stock Ascendis Pharma reversed early losses Thursday to close with a gain despite a first-quarter miss for Skytrofa.

Among the best credit cards for groceries, the Blue Cash Preferred Card and Blue Cash Everyday Card offer high rewards rates at U.S. supermarkets.

CRYPTO UPDATE All of the largest cryptocurrencies were up during morning trading on Friday, with Polkadot (DOTUSD) seeing the biggest move, rocketing 35.22% to $11.60. Cardano (ADAUSD) soared 22.07% to 58 cents, while Ripple (XRPUSD) jumped 17.

Wealthy people often are divided into two categories, high-net-worth individuals (HNWIS) who have at least $1 million in liquid assets and ultra-high-net-worth individuals (UHNWIS) with $30 million and up. The definitions matter to the financial services industry, which targets different … Continue reading → The post High-Net-Worth vs. Ultra-High-Net-Worth appeared first on SmartAsset Blog.